ArticleTherapeutic advances in medical oncology2026
CD71 as an independent prognostic factor in pediatric B-ALL: a regional multicenter retrospective study in Southern China (SCCLG-ALL-2016).
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite high cure rates in pediatric B-cell acute lymphoblastic leukemia (B-ALL), relapse remains a major challenge. Current risk stratification systems fail to identify a subset of occult high-risk (HR) patients. Transferrin receptor 1 (CD71), a key regulator of iron uptake, is often overexpressed in aggressive tumors; however, its independent prognostic value in pediatric B-ALL has not been fully elucidated. Objectives: To evaluate the independent prognostic significance of CD71 expression in a large cohort of pediatric B-ALL patients and to determine its utility in identifying HR subgroups. Design: A retrospective, multicenter cohort study. Methods: We analyzed 1207 pediatric B-ALL patients treated under the South China Children's Leukemia Group-ALL-2016 protocol between January 2016 and June 2023 across 20 centers in Southern China. CD71 expression was assessed by flow cytometry at diagnosis, with positivity defined as ⩾20% expression on blast cells. We analyzed associations between CD71 status, clinical characteristics, and survival outcomes using Kaplan-Meier methods and multivariate Cox regression models. Results: CD71 positivity was rare in B-ALL (1.0%) compared to T-ALL (15.6%). Clinically, CD71-positive B-ALL patients presented with significantly lower initial white blood cell (WBC) counts (median 4.0 vs 10.0 × 10 Conclusion: CD71 expression identifies a rare but biologically distinct B-ALL subgroup characterized by aggressive behavior despite low initial WBC counts. These findings indicate that the inclusion of CD71 in diagnostic panels may help to optimize current risk stratification systems, serving as a critical tool to recognize occult HR patients who might otherwise be under-stratified by conventional prognostic markers. Clinical trial registration: The trial is registered with the Chinese Clinical Trial Registry (Chi-CTR; https://www.chictr.org.cn/; number ChiCTR2000030357; Registration date: February 29, 2020).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.